NCT01845493已完成1 期
Sulforaphane Supplementation in Atopic Asthmatics
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 16
- 试验地点
- 2
- 主要终点
- mRNA levels of NRF2 and NRF2-dependent phase II enzymes in nasal epithelial cells
研究概览
简要总结
The investigators will perform a pilot study of daily treatment with oral sulforaphane (SFN) for 3 days to determine if Nuclear factor (erythroid-derived 2)-like 2 (NRF2) induction is possible with this supplementation regimen in individuals with allergic asthma.
详细描述
This pilot study will examine if oral SFN supplementation can induce NRF2 and NRF2-dependent phase II enzymes in nasal epithelial cells of allergic asthmatics. Subjects will receive both a SFN-rich broccosprout homogenate preparation and an alfalfa sprout homogenate (placebo) in a crossover fashion. mRNA levels of NRF2 and NRF2-dependent phase II enzymes will be compared between the active and placebo periods.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 50 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age 18-50 of both genders
- •History of episodic wheezing, chest tightness, or shortness of breath after age of 6 years consistent with asthma, or physician diagnosed asthma after age of 6 years.
- •AND: Positive methacholine test. A positive test is defined as a provocative concentration of methacholine of 10 mg/ml or less producing a 20% fall in FEV1 (PC20 methacholine). Methacholine challenge in a separate screening protocol (98-0799), or from other venues will be accepted.
- •OR: Pre and post bronchodilator FEV1 improvement by 12% or more after 4 puffs of albuterol inhaler.
- •FEV1 of at least 80% of predicted and FEV1/FVC ratio of at least .70 (without use of bronchodilating medications for 12 hours), consistent with lung function of persons with no more than mild episodic or mild persistent asthma (NHANES III predicted set).
- •Allergic sensitization to at least one of the following allergen preparations: (House Dust Mite f, House dust mite p, Cockroach, Tree mix, Grass Mix, Weed Mix, Mold Mix 1, Mold Mix 2, Rat, Mouse, Guinea Pig, Rabbit, Cat or Dog) confirmed by positive immediate skin test response in a separate screening protocol. Proof of allergy from other venues, including ImmunoCAP testing from a medical workup, provided by the subject, will be accepted.
- •Oxygen saturation of > 94 % and normal blood pressure (Systolic between 150 - 90, Diastolic between 90-60 mm Hg)
- •Willing to provide information regarding health history and habits of cigarette smoke exposure;
- •Willing to avoid antioxidant vitamins and cruciferous vegetables as well as juices/drinks with added vitamin supplements for 2 days prior the baseline screening visit and throughout initial dosing period.
- •Subjects must be willing to avoid antihistamine use for 4 days prior to each session and NSAIDs for 7 days prior to each session. Nasal steroids must be held for 2 weeks prior to the session.
排除标准
- •Medical history or underlying health problems that preclude participation in the protocol per the study physician;
- •Current nutritional disorder such as anorexia, bulimia, irritable bowel syndrome, Crohn's disease etc;
- •Use of oral corticosteroids within the past 4 weeks;
- •Presence of upper or lower respiratory tract infection or treatment with antibiotics within the previous 4 weeks;
- •Pregnancy as determined by menstrual history or urine pregnancy test;
- •Current smokers will be excluded. Anyone with a smoking history > 0.5 pack year and/or >1 pack per month will also be excluded.
- •History of bleeding disorder;
- •Recent nasal surgery (with 6 months). If a subject has had nasal surgery between 6 months and 5 years, a study physician will visualize the area prior to the biopsy to evaluate the suitability of the nose for the procedure.
- •History of intolerance of or aversion to broccoli
- •Unable to withhold nasal steroids for 2 weeks before each session. These subjects may be deferred until after their allergy season.
结局指标
主要结局
mRNA levels of NRF2 and NRF2-dependent phase II enzymes in nasal epithelial cells
时间窗: 2 hours post third ingestion of SFN/placebo ingestion
次要结局
未报告次要终点
研究者
Michelle Hernandez, MD
Principle Investigator
University of North Carolina, Chapel Hill
研究点 (2)
Loading locations...
相似试验
Unknown
4 期
A Pilot Study on Effect of add-on Sulforaphane to SSRIs and Application of Niacin Skin Flush Response Test in Major Depressive DisorderMajor Depressive DisorderNCT05148169Shanghai Mental Health Center150
已完成
早期 1 期
Pilot Study Evaluating Sulforaphane in Atypical Nevi-Precursor LesionsAtypical NeviMelanomaNCT01568996John Kirkwood17
已完成
2 期
A 6-month Study to Evaluate Sulforaphane Effects in Schizophrenia PatientsSchizophreniaNCT04521868Central South University125
进行中（未招募）
2 期
Sulforaphane in a New Jersey (NJ) Population of Individuals With AutismAutistic DisorderAutistic BehaviorAutismAutism Spectrum DisorderNCT02677051Rutgers, The State University of New Jersey48
Unknown
不适用
Pilot Study to Assess Tolerability and Feasibility of Oral Sulfate Solution (SUPREP) in Hospitalized PatientsInpatient ColonoscopyOral Sulfate SolutionPolyethelene GlycolNCT04504292University of Virginia124